Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.

Reisenbichler ES, Adams AL, Hameed O.

Am J Clin Pathol. 2013 Dec;140(6):767-79. doi: 10.1309/AJCPXV64GXLZCIGA.

PMID:
24225742
2.

Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction.

Reisenbichler ES, Balmer NN, Adams AL, Pfeifer JD, Hameed O.

Mod Pathol. 2011 Feb;24(2):185-93. doi: 10.1038/modpathol.2010.197. Epub 2010 Nov 12.

3.

An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas.

Wang Y, Zhu JF, Liu YY, Han GP.

Diagn Pathol. 2013 Jan 18;8:8. doi: 10.1186/1746-1596-8-8.

4.

The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.

Ding Y, Ruan Q.

J Huazhong Univ Sci Technolog Med Sci. 2006;26(4):405-7.

PMID:
17120733
5.

Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.

Grin A, O'Malley FP, Mulligan AM.

Am J Surg Pathol. 2009 Nov;33(11):1615-23. doi: 10.1097/PAS.0b013e3181aec446.

PMID:
19675450
6.

The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW.

J Clin Pathol. 2007 Mar;60(3):315-20. Epub 2006 May 12.

7.

The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.

Reisenbichler ES, Ross JR, Hameed O.

Ann Diagn Pathol. 2014 Dec;18(6):313-8. doi: 10.1016/j.anndiagpath.2014.08.007. Epub 2014 Aug 27.

PMID:
25224390
8.

Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy.

Sydnor MK, Wilson JD, Hijaz TA, Massey HD, Shaw de Paredes ES.

Radiology. 2007 Jan;242(1):58-62. Epub 2006 Nov 7.

PMID:
17090707
9.

Diagnostic evaluation of papillary lesions of the breast on core biopsy.

Pathmanathan N, Albertini AF, Provan PJ, Milliken JS, Salisbury EL, Bilous AM, Byth K, Balleine RL.

Mod Pathol. 2010 Jul;23(7):1021-8. doi: 10.1038/modpathol.2010.81. Epub 2010 May 14.

10.

Usefulness of immunocytochemistry using a Breast Marker antibody cocktail targeting P63/cytokeratin7/18/cytokeratin5/14 for fine needle aspiration of the breast: a retrospective cohort study of 139 cases.

Tanaka S, Kanomata N, Teramura K, Wakita K, Kunihisa T, Yano Y, Moriya T, Hayashi Y.

Cytopathology. 2016 Dec;27(6):465-471. doi: 10.1111/cyt.12335. Epub 2016 Apr 6.

PMID:
27060708
11.

The diagnostic utility of CK5/6 and p63 in fine-needle aspiration of the breast lesions diagnosed as proliferative fibrocystic lesion.

Al-Maghraby H, Ghorab Z, Khalbuss W, Wong J, Silverman JF, Saad RS.

Diagn Cytopathol. 2012 Feb;40(2):141-7. doi: 10.1002/dc.21534. Epub 2010 Dec 8.

PMID:
22246930
12.

Quantitative expression study of four cytokeratins and p63 in squamous cell carcinoma of the tongue: suitability for sentinel node navigation surgery using one-step nucleic acid amplification.

Yamauchi K, Fujioka Y, Kogashiwa Y, Kohno N.

J Clin Pathol. 2011 Oct;64(10):875-9. doi: 10.1136/jclinpath-2011-200085. Epub 2011 Jun 24.

PMID:
21705376
13.

Papillary lesions initially diagnosed at ultrasound-guided vacuum-assisted breast biopsy: rate of malignancy based on subsequent surgical excision.

Chang JM, Han W, Moon WK, Cho N, Noh DY, Park IA, Jung EJ.

Ann Surg Oncol. 2011 Sep;18(9):2506-14. doi: 10.1245/s10434-011-1617-3. Epub 2011 Mar 3.

PMID:
21369740
14.

Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens.

Shah VI, Flowers CI, Douglas-Jones AG, Dallimore NS, Rashid M.

Histopathology. 2006 May;48(6):683-91.

PMID:
16681684
15.

Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses.

Jakate K, De Brot M, Goldberg F, Muradali D, O'Malley FP, Mulligan AM.

Am J Surg Pathol. 2012 Apr;36(4):544-51. doi: 10.1097/PAS.0b013e318243fa00.

PMID:
22314186
16.

Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?

Tan PH, Aw MY, Yip G, Bay BH, Sii LH, Murugaya S, Tse GM.

Am J Surg Pathol. 2005 May;29(5):625-32.

PMID:
15832086
17.
18.

Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.

de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Vassallo J, Alvarenga M.

Breast J. 2008 Jan-Feb;14(1):68-75. Epub 2007 Dec 11.

PMID:
18086274
19.
20.

Mammary lesions diagnosed as "papillary" by aspiration biopsy: 70 cases with follow-up.

Simsir A, Waisman J, Thorner K, Cangiarella J.

Cancer. 2003 Jun 25;99(3):156-65.

Supplemental Content

Support Center